Clint Witchalls

Brixton, London

Senior Health Editor at The Conversation

Senior health editor @ConversationUK Views are my own.

Featured in: Favicon

Articles

Wegovy has arrived in the UK: the story of the weight-loss jab so far

Sep 6, 2023 | tolerance.ca | Clint Witchalls

© 2023 Tolerance.ca® Inc. All reproduction rights reserved. All information reproduced on the Web pages of www.tolerance.ca (including articles, images, photographs, and logos) is protected by intellectual property rights owned by Tolerance.ca® Inc. or, in certain cases, by its author. Any reproduction of the information for use other than personal use is prohibited.
Wegovy has arrived in the UK: the story of the weight-loss jab so far

Sep 6, 2023 | theconversation.com | Clint Witchalls

In February 2021, The Conversation reported on a trial for a new weight-loss drug, called semaglutide, that was being hailed in the media as a “gamechanger”. Gamechanger is a word used far too often by journalists to describe things that are, frankly, mundane. This time, though, the word seems apt. In the past two and a half years, a lot of ink has been spilt discussing the merits and demerits of this drug – better known by its brand names Ozempic and Wegovy – including in The Conversation.